FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000748433> ?p ?o ?g. }

• W2000748433 endingPage "12" @default.
• W2000748433 startingPage "8" @default.
• W2000748433 abstract "Alpha-1 antitrypsin (AAT) has broad anti-inflammatory and immunomodulating properties in addition to inhibiting serine proteases. Administration of human plasma–derived AAT is protective in models of acute myocardial infarction in mice. The objective of this study was to determine the safety and tolerability of human plasma–derived AAT and its effects on the acute inflammatory response in non-AAT deficient patients with ST-segment elevation myocardial infarction (STEMI). Ten patients with acute STEMI were enrolled in an open-label, single-arm treatment study of AAT at 60 mg/kg infused intravenously within 12 hours of admission and following standard of care treatment. C-reactive protein (CRP) and plasma AAT levels were determined at admission, 72 hours, and 14 days, and patients were followed clinically for 12 weeks for the occurrence of new onset heart failure, recurrent myocardial infarction, or death. Twenty patients with STEMI enrolled in previous randomized trials with identical inclusion and/or exclusion criteria, but who received placebo, served as historical controls. Prolastin C was well tolerated and there were no in-hospital adverse events. Compared with historical controls, the area under the curve of CRP levels was significantly lower 14 days after admission in the Prolastin C group (75.9 [31.4 to 147.8] vs 205.6 [78.8 to 410.9] mg/l, p = 0.048), primarily due to a significant blunting of the increase occurring between admission and 72 hours (delta CRP +1.7 [0.2 to 9.4] vs +21.1 [3.1 to 38.0] mg/l, p = 0.007). Plasma AAT levels increased from admission (149 [116 to 189]) to 203 ([185 to 225] mg/dl) to 72 hours (p = 0.005). In conclusion, a single administration of Prolastin C in patients with STEMI is well tolerated and is associated with a blunted acute inflammatory response. Alpha-1 antitrypsin (AAT) has broad anti-inflammatory and immunomodulating properties in addition to inhibiting serine proteases. Administration of human plasma–derived AAT is protective in models of acute myocardial infarction in mice. The objective of this study was to determine the safety and tolerability of human plasma–derived AAT and its effects on the acute inflammatory response in non-AAT deficient patients with ST-segment elevation myocardial infarction (STEMI). Ten patients with acute STEMI were enrolled in an open-label, single-arm treatment study of AAT at 60 mg/kg infused intravenously within 12 hours of admission and following standard of care treatment. C-reactive protein (CRP) and plasma AAT levels were determined at admission, 72 hours, and 14 days, and patients were followed clinically for 12 weeks for the occurrence of new onset heart failure, recurrent myocardial infarction, or death. Twenty patients with STEMI enrolled in previous randomized trials with identical inclusion and/or exclusion criteria, but who received placebo, served as historical controls. Prolastin C was well tolerated and there were no in-hospital adverse events. Compared with historical controls, the area under the curve of CRP levels was significantly lower 14 days after admission in the Prolastin C group (75.9 [31.4 to 147.8] vs 205.6 [78.8 to 410.9] mg/l, p = 0.048), primarily due to a significant blunting of the increase occurring between admission and 72 hours (delta CRP +1.7 [0.2 to 9.4] vs +21.1 [3.1 to 38.0] mg/l, p = 0.007). Plasma AAT levels increased from admission (149 [116 to 189]) to 203 ([185 to 225] mg/dl) to 72 hours (p = 0.005). In conclusion, a single administration of Prolastin C in patients with STEMI is well tolerated and is associated with a blunted acute inflammatory response." @default.
• W2000748433 created "2016-06-24" @default.
• W2000748433 creator A5006905071 @default.
• W2000748433 creator A5011025826 @default.
• W2000748433 creator A5017216920 @default.
• W2000748433 creator A5021405108 @default.
• W2000748433 creator A5022158087 @default.
• W2000748433 creator A5028234430 @default.
• W2000748433 creator A5049190203 @default.
• W2000748433 creator A5049273996 @default.
• W2000748433 creator A5050637981 @default.
• W2000748433 creator A5052105348 @default.
• W2000748433 creator A5054197461 @default.
• W2000748433 creator A5071161224 @default.
• W2000748433 creator A5073353856 @default.
• W2000748433 creator A5080976772 @default.
• W2000748433 creator A5088023841 @default.
• W2000748433 creator A5088235841 @default.
• W2000748433 date "2015-01-01" @default.
• W2000748433 modified "2023-09-25" @default.
• W2000748433 title "Effects of Prolastin C (Plasma-Derived Alpha-1 Antitrypsin) on the Acute Inflammatory Response in Patients With ST-Segment Elevation Myocardial Infarction (from the VCU-Alpha 1-RT Pilot Study)" @default.
• W2000748433 cites W1967169823 @default.
• W2000748433 cites W2026770496 @default.
• W2000748433 cites W2027132059 @default.
• W2000748433 cites W2032049229 @default.
• W2000748433 cites W2040610145 @default.
• W2000748433 cites W2058474974 @default.
• W2000748433 cites W2074130375 @default.
• W2000748433 cites W2100950823 @default.
• W2000748433 cites W2107198585 @default.
• W2000748433 cites W2142208862 @default.
• W2000748433 cites W2151830751 @default.
• W2000748433 cites W2168576606 @default.
• W2000748433 doi "https://doi.org/10.1016/j.amjcard.2014.09.043" @default.
• W2000748433 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25456867" @default.
• W2000748433 hasPublicationYear "2015" @default.
• W2000748433 type Work @default.
• W2000748433 sameAs 2000748433 @default.
• W2000748433 citedByCount "39" @default.
• W2000748433 countsByYear W20007484332015 @default.
• W2000748433 countsByYear W20007484332016 @default.
• W2000748433 countsByYear W20007484332017 @default.
• W2000748433 countsByYear W20007484332018 @default.
• W2000748433 countsByYear W20007484332019 @default.
• W2000748433 countsByYear W20007484332020 @default.
• W2000748433 countsByYear W20007484332021 @default.
• W2000748433 countsByYear W20007484332022 @default.
• W2000748433 countsByYear W20007484332023 @default.
• W2000748433 crossrefType "journal-article" @default.
• W2000748433 hasAuthorship W2000748433A5006905071 @default.
• W2000748433 hasAuthorship W2000748433A5011025826 @default.
• W2000748433 hasAuthorship W2000748433A5017216920 @default.
• W2000748433 hasAuthorship W2000748433A5021405108 @default.
• W2000748433 hasAuthorship W2000748433A5022158087 @default.
• W2000748433 hasAuthorship W2000748433A5028234430 @default.
• W2000748433 hasAuthorship W2000748433A5049190203 @default.
• W2000748433 hasAuthorship W2000748433A5049273996 @default.
• W2000748433 hasAuthorship W2000748433A5050637981 @default.
• W2000748433 hasAuthorship W2000748433A5052105348 @default.
• W2000748433 hasAuthorship W2000748433A5054197461 @default.
• W2000748433 hasAuthorship W2000748433A5071161224 @default.
• W2000748433 hasAuthorship W2000748433A5073353856 @default.
• W2000748433 hasAuthorship W2000748433A5080976772 @default.
• W2000748433 hasAuthorship W2000748433A5088023841 @default.
• W2000748433 hasAuthorship W2000748433A5088235841 @default.
• W2000748433 hasConcept C126322002 @default.
• W2000748433 hasConcept C141071460 @default.
• W2000748433 hasConcept C142724271 @default.
• W2000748433 hasConcept C164705383 @default.
• W2000748433 hasConcept C197934379 @default.
• W2000748433 hasConcept C204787440 @default.
• W2000748433 hasConcept C27081682 @default.
• W2000748433 hasConcept C2771771 @default.
• W2000748433 hasConcept C2775944032 @default.
• W2000748433 hasConcept C2776291336 @default.
• W2000748433 hasConcept C2778198053 @default.
• W2000748433 hasConcept C2778375690 @default.
• W2000748433 hasConcept C49453240 @default.
• W2000748433 hasConcept C500558357 @default.
• W2000748433 hasConcept C64943373 @default.
• W2000748433 hasConcept C71924100 @default.
• W2000748433 hasConcept C90924648 @default.
• W2000748433 hasConceptScore W2000748433C126322002 @default.
• W2000748433 hasConceptScore W2000748433C141071460 @default.
• W2000748433 hasConceptScore W2000748433C142724271 @default.
• W2000748433 hasConceptScore W2000748433C164705383 @default.
• W2000748433 hasConceptScore W2000748433C197934379 @default.
• W2000748433 hasConceptScore W2000748433C204787440 @default.
• W2000748433 hasConceptScore W2000748433C27081682 @default.
• W2000748433 hasConceptScore W2000748433C2771771 @default.
• W2000748433 hasConceptScore W2000748433C2775944032 @default.
• W2000748433 hasConceptScore W2000748433C2776291336 @default.
• W2000748433 hasConceptScore W2000748433C2778198053 @default.
• W2000748433 hasConceptScore W2000748433C2778375690 @default.
• W2000748433 hasConceptScore W2000748433C49453240 @default.
• W2000748433 hasConceptScore W2000748433C500558357 @default.
• W2000748433 hasConceptScore W2000748433C64943373 @default.
• W2000748433 hasConceptScore W2000748433C71924100 @default.

• next